Health Minister Fahrettin Koca, a meeting is more related to its ongoing vaccine trials carried out in Turkey by announcing "Public, all resources have been mobilized to make the vaccine widely used in our candidates," he said.
Minister Koca used the following statements; We held another meeting in our ministry to evaluate the latest situation of domestic vaccines. Meeting project with our teacher, Turkey Pharmaceuticals and Medical Devices Agency (TİTCK) President, Turkey Institutes of Health (TÜSEB) Chairman, President and TUBITAK Our Ministry officials attended. We brought together all the components of vaccine studies and evaluated the current situation and discussed future strategies.
In our country, we have 17 different vaccine candidates whose development process continues. Our inactivated vaccine candidate, who is in the phase of human trials, is about to start Phase II human trials. Preparations for this vaccine candidate for widespread use are ongoing by coming to the Phase III human trial phase in April. In addition, 3 inactivated vaccine candidates are in Phase I human trial phase. Our Turkey Pharmaceuticals and Medical Devices Agency (TİTCK) allows for human experiments by examining the work done before human trials.
Currently, our 3 inactive vaccine candidates have applied to TITCK for permission for human experiments and have reached the stage where they can start human experiments. Two of our candidate vaccines based on adanovirus have completed the pre-clinical stages and applied to TITCK.
Our Virus-Like Particle (VLP) vaccine candidate, which is a first in the world, has also reached the stage of obtaining the research product and is soon to apply for permission for human experiments. Our other vaccine candidates are at various pre-clinical stages.
Examinations of all facilities that can produce vaccines in our country have been completed and Good Manufacturing Practices (GMP) certification processes have been completed. Our institutions continue to work with all their might for the rapid implementation of our vaccine candidates. Our country's scientific capacity is capable of conducting research and development activities for all vaccine types.
Our country's clinical research experience is at the level to evaluate our vaccine candidates during human trials.
I believe that the scientific and technical infrastructure of our country and the perseverance and effort of our Scientists will bring us the best vaccines. The public has mobilized all its resources to make our vaccine candidates widely available.